Treating Advanced Metastatic Pancreatic Cancer: Current Challenges and Future Opportunities

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: January 23, 2019
Expiration Date: January 23, 2020

Expected time to complete this activity as designed: 30 minutes

There are no fees for participating in or receiving credit for this online activity.

Program Overview

Pancreatic cancer is the hardest to treat out of any major cancer, both biologically and clinically, which is why clinicians face so many unique challenges. However, there are efforts being taken to improve patient outcomes. In this activity, Dr. Vincent Picozzi from the Virginia Mason Medical Center will outline the current pipeline across advanced metastatic pancreatic cancer treatment. He will also summarize recent findings regarding risk factors, biology, and multimodality treatment.

Target Audience

This activity is designed for multidisciplinary healthcare providers in the community setting, including oncologists, pharmacists and other allied healthcare professionals who provide care to patients with pancreatic cancer.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Define the unique challenges associated with pancreatic cancer, including the role of tumor microenvironment, inflammation, and stroma as it relates to the development of treatment options
  • Summarize recent progress and new findings regarding pancreatic cancer risk factors, biology, diagnosis, and multimodality treatments
  • Outline the current pipeline across pancreatic cancer treatment, focusing on new potential therapeutic strategies or combination therapies that may advance treatment options


Treating Advanced Metastatic Pancreatic Cancer: Current Challenges and Future Opportunities – Vincent J. Picozzi, Jr., MD, MMM

Instructions for Participation and Credit

This activity is eligible for credit through January 23, 2020. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biography

Vincent Picozzi, Jr., MD, MMM
Pancreas Center of Excellence
Digestive Disease Institute
Virginia Mason Medical Center
Seattle, Washington

Dr. Vincent Picozzi received his medical degree from Stanford University in Stanford, California. He completed his internship and residency at Harvard University, Brigham and Women’s Hospital, and returned to Stanford University to complete his fellowships in hematology and oncology. In addition, Dr. Picozzi has completed a master of medical management (MMM) degree at Tulane University. He is currently Director of the Pancreas Center of Excellence, Digestive Disease Institute, as well as a practicing physician in the Division of Hematology-Oncology, at Virginia Mason Medical Center in Seattle, Washington.

Dr. Picozzi has board certification from National Board of Medical Examiners and from the American Board of Internal Medicine in internal medicine, hematology, and oncology. He holds professional memberships in the American Society of Clinical Oncology (ASCO), American Society of Hematology (ASH), and the Pancreatic Cancer Action Network (PANCAN). He is on the Board of Directors (and a founding member) of the Washington State Medical Oncology Society, as well as the Providence Hospice of King County Foundation.

Serving patients with hematologic and oncologic disorders is Dr. Picozzi’s calling in life. His mission is to elevate the relationship between cancer patients and their providers to a premier level of importance in our society. In particular, serving patients with pancreaticobiliary cancer has been the central ministry of his professional career. His immediate goal is to assist in the transformation of perceptions and outcomes for this disorder that has the poorest prognosis of any common cancer.


Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.5 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-19-001-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.


As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosure

Dr. Vincent Picozzi has received grant support related to research activities from Celgene Corporation, Eli Lilly and Company, FibroGen, Inc., Halozyme, Inc., Ipsen, OncoMed Pharmaceuticals, Inc., Taiho Pharmaceutical Co., Ltd., Takeda Oncology, and Tyme Inc.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Andrea Mathis, Project Manager, and Joan Meyer, RN, MHA, Executive Director, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Celgene Corporation

©2019 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

MediCom Worldwide, Inc. would like to thank Celgene Corporation for their educational support of

©2020 MediCom Worldwide, Inc. All rights reserved